Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice.
作者： Cathrine L. Denton , Daniel L. Gustafson
DOI: 10.1007/S00280-010-1323-Z
关键词:
摘要: Purpose AZD6244 (ARRY-142886) (AstraZeneca, Macclesfield, UK) is a novel small molecule MEK1/2 inhibitor that currently being tested in Phase II trials. With the recent publication of human pharmacokinetic data from clinical studies, we now know achievable levels and range AZD6244 exposure humans. This study aimed to describe profile mice order design preclinical studies recapitulate
springer.com
sci-hub.se 参考文章(21)
Tumor Models in Cancer Research Humana Press. ,(2001) , 10.1007/978-1-60761-968-0
Marcia S Brose, Patricia Volpe, Michael Feldman, Madhu Kumar, Irum Rishi, Renee Gerrero, Eugene Einhorn, Meenhard Herlyn, John Minna, Andrew Nicholson, Jack A Roth, Steven M Albelda, Helen Davies, Charles Cox, Graham Brignell, Philip Stephens, P Andrew Futreal, Richard Wooster, Michael R Stratton, Barbara L Weber, None, BRAF and RAS mutations in human lung cancer and melanoma Cancer Research. ,vol. 62, pp. 6997- 7000 ,(2002)
Esther Edlundh-Rose, Suzanne Egyha??zi, Katarina Omholt, Eva Mansson-Brahme, Anton Platz, Johan Hansson, Joakim Lundeberg, NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing Melanoma Research. ,vol. 16, pp. 471- 478 ,(2006) , 10.1097/01.CMR.0000232300.22032.86
Jenny N. Poynter, James T. Elder, Douglas R. Fullen, Rajan P. Nair, Maria S. Soengas, Timothy M. Johnson, Bruce Redman, Nancy E. Thomas, Stephen B. Gruber, BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Research. ,vol. 16, pp. 267- 273 ,(2006) , 10.1097/01.CMR.0000222600.73179.F3
Douglas W. Ball, Ning Jin, D. Marc Rosen, Alan Dackiw, David Sidransky, Mingzhao Xing, Barry D. Nelkin, Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. The Journal of Clinical Endocrinology and Metabolism. ,vol. 92, pp. 4712- 4718 ,(2007) , 10.1210/JC.2007-1184
N. K. Haass, K. Sproesser, T. K. Nguyen, R. Contractor, C. A. Medina, K. L. Nathanson, M. Herlyn, K. S.M. Smalley, The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel Clinical Cancer Research. ,vol. 14, pp. 230- 239 ,(2008) , 10.1158/1078-0432.CCR-07-1440
Vikas K. Goel, Alexander J.F. Lazar, Carla L. Warneke, Mark S. Redston, Frank G. Haluska, Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma Journal of Investigative Dermatology. ,vol. 126, pp. 154- 160 ,(2006) , 10.1038/SJ.JID.5700026
David B. Solit, Levi A. Garraway, Christine A. Pratilas, Ayana Sawai, Gad Getz, Andrea Basso, Qing Ye, Jose M. Lobo, Yuhong She, Iman Osman, Todd R. Golub, Judith Sebolt-Leopold, William R. Sellers, Neal Rosen, BRAF mutation predicts sensitivity to MEK inhibition Nature. ,vol. 439, pp. 358- 362 ,(2006) , 10.1038/NATURE04304
K S M Smalley, R Contractor, N K Haass, J T Lee, K L Nathanson, C A Medina, K T Flaherty, M Herlyn, Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels British Journal of Cancer. ,vol. 96, pp. 445- 449 ,(2007) , 10.1038/SJ.BJC.6603596
Lena Kanter, Johan Hansson, Anton Platz, Ulrik Ringborg, Katarina Omholt, NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clinical Cancer Research. ,vol. 9, pp. 6483- 6488 ,(2003)